4′-bis(2-bromoacetyl)biphenyl_Kain Industrial Additive

background and overview[1] 4,4’-bis(2-bromoacetyl)biphenyl is a key intermediate in the synthesis of the anti-hepatitis c drug daclatasvir. daclatasvir is a new hepatitis c drug developed by bristol-myers squibb in the united states. on july 24, 2015, the u.s. fda approved it for the treatment of chronic hepatitis c. the trade name is daklinza. it is…